Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-572270 in Advanced Solid Tumors With RAS Mutations
NCT07435038Phase 2Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of BPI-572270 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), solid tumor, sponsored by Betta Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
BPI-572270
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT07435038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435038.